<DOC>
	<DOCNO>NCT01486979</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial evaluate extent systemic absorption estradiol treatment two different dos estradiol postmenopausal woman atrophic vaginitis .</brief_summary>
	<brief_title>Pharmacokinetic Assessment Absorption Estradiol Postmenopausal Women With Atrophic Vaginitis</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Atrophic Vaginitis</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Subjects able use German language speak write Postmenopausal woman least 5 year last menstruation , bilateral oophorectomy perform two year prior time screen Serum FSH ( Follicle Stimulating Hormone ) level 40 mIU/ml estradiol 20 pg/ml Maximum 5 % superficial cell assess evaluation vaginal cytology Endometrial thickness 4.0 mm ( double layer ) , measure transvaginal ultrasound ( applicable ) Availability normal mammogram within one year prior trial start Good general health assess Investigator base medical history , physical laboratory examination Known suspect allergy trial product related product Known , suspect past history breast cancer Known , suspect past estrogen dependent neoplasia e.g . endometrial cancer Endometrial hyperplasia endometrial polyp diagnose screen period Abnormal genital bleed unknown etiology Previous estrogen and/ progestin hormone replacement therapy</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>